Ads
related to: hsv 2 igg false positive ratehealthlabs.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Relative to rates in Europe and North America, HSV-2 seroprevalency is high in Central and South America. Infection levels are estimated at 20% to 60%. [3] [24] During the mid-1980s, HSV-2 prevalence was 33% in 25- to 29-year-old women and 45% in those aged 40 and over in Costa Rica. In the early 1990s HSV-2 prevalence was approximately 45% ...
Herpes simplex virus 1 (cold sores) and 2 (genital herpes) (HSV-1 and HSV-2), also known by their taxonomic names Human alphaherpesvirus 1 and Human alphaherpesvirus 2, are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. [1] [2] Both HSV-1 and HSV-2 are very common and ...
Worldwide rates of either HSV-1 and/or HSV-2 are between 60 and 95% in adults. [4] HSV-1 is more common than HSV-2, with rates of both increasing as people age. [4] HSV-1 rates are between 70% and 80% in populations of low socioeconomic status and 40% to 60% in populations of improved socioeconomic status. [4]
The false positive rate (FPR) is the proportion of all negatives that still yield positive test outcomes, i.e., the conditional probability of a positive test result given an event that was not present. The false positive rate is equal to the significance level. The specificity of the test is equal to 1 minus the false positive rate.
False negative test results may occur if the test is performed late in the course of the illness or if the test sample is not appropriately acquired. [17] Testing people for HSV when they are asymptomatic is not recommended due to the high false-positivity rate. [18] A false positive test may cause relationship difficulties. [18]
Serological assays may give a false positive result, causing the individual to appear to have seroconverted when the individual has not. False positives can occur due to the test reacting to, or detecting, an antibody that happens to be sufficiently similar in structure to the target antibody.